About Beverly Biller, MD

Beverly MK Biller, MD is an endocrinologist in the Massachusetts General Hospital (MGH) Neuroendocrine Clinical Center.  She is a faculty member in the Neuroendocrine Unit at MGH and a Professor of Medicine at Harvard Medical School.  Dr. Biller's major clinical and research interests include the diagnosis and treatment of Cushing's disease, prolactinomas, acromegaly, other pituitary tumors and sellar masses, and pituitary hormone deficiencies in adults.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Neuroendocrine and Pituitary Tumor Clinical Center
55 Fruit Street
Cox 140
Boston, MA 02114-2696
617-726-7948
Fax: 617-726-1241

Medical Education

  • MD, University of Oklahoma College of Medicine
  • Residency, Beth Israel Deaconess Medical Center
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Endocrinology, Diabetes & Metabolism, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Biller is a clinical investigator who focuses on pituitary disorders.  Major research interests include the diagnosis and treatment of Cushing's disease, prolactinomas, acromegaly, other pituitary tumors and sellar masses as well as pituitary hormone deficiencies, including growth hormone deficiency in adults. 

Publications

  • Selected research publications from 2012-2013

    • van der Lely et al Long-Term Safety of Pegvisomant in Patients with Acromegaly...J Clin Endocrinol Metab. 2012 May; 97(5):1589
    • Fleseriu et al Mifepristone, a glucocorticoid receptor antagonist.... J Clin Endocrinol Metab. 2012 Jun;97(6):2039
    • Colao et al A 12-month phase III study of pasireotide in Cushing’s disease. N Engl J Med. 2012; 366:914
    • Biller et al 12-Month effects of once-weekly sustained-release growth hormone treatment... Pituitary. 2012 Aug 23
    • Bertagna et al LCI699, a potent 11ß-hydroxylase inhibitor, normalizes urinary cortisol ... J Clin Endocrinol Metab. 2013 Dec 10